Table 3.
Estimated probability (%) of a treatment being the most effective in reducing the risk of a dichotomous outcome for all studies
| Outcomes | Treatments | ||
|---|---|---|---|
| Metformin | Glyburide | Insulin | |
| Adverse maternal outcomes † | 29.5 | 70.5 | 0.0 |
| Adverse neonatal outcomes ‡ | 90.6 | 9.3 | 0.1 |
| Excessive fetal growth | 99.9 | 0.1 | 0.0 |
| Hypertensive disorders of pregnancy | 99.7 | 0.2 | 0.1 |
| Neonatal metabolic disturbance | 99.7 | 0.2 | 0.1 |
| Serious neonatal conditions | 1.8 | 98.2 | 0.0 |
| Abnormal delivery | 0.0 | 100.0 | 0.0 |
| LGA | 99.8 | 0.2 | 0.0 |
| Macrosomia | 97.9 | 1.8 | 0.4 |
| Hyperbilirubinaemia | 75.4 | 22.3 | 2.3 |
| Induction of labor | 88.9 | 8.4 | 2.8 |
| NICU admission | 88.0 | 12.0 | 0.0 |
| Pre‐eclampsia | 62.9 | 32.5 | 4.6 |
| PIH | 84.7 | 15.3 | 0.0 |
| Preterm birth | 56.8 | 33.2 | 10.0 |
| Neonatal hypoglycemia | 99.9 | 0.1 | 0.0 |
| SGA | 43.6 | 45.5 | 10.9 |
| Maternal hypoglycemia | 1.1 | 98.9 | 0.0 |
| Respiratory distress syndrome | 7.1 | 88.2 | 4.7 |
| Shoulder dystocia | 38.9 | 48.0 | 13.1 |
| Congenital abnormality | 28.7 | 67.2 | 4.2 |
| Cesarean section | 18.3 | 79.7 | 2.0 |
| Perinatal mortality | 38.9 | 12.6 | 48.4 |
†
Adverse maternal outcomes including: induction of labor, pre‐eclampsia, pregnancy‐induced hypertension (PIH), maternal hypoglycemia and cesarean section.
‡
Adverse neonatal outcomes including: large for gestational age (LGA), macrosomia, hyperbilirubinemia, neonatal intensive care unit (NICU) admission, preterm birth, small for gestational age (SGA), neonatal hypoglycemia, respiratory distress syndrome, shoulder dystocia and congenital abnormality.